http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
분자체 13X에 의한 산소 및 질소의 확산에 관한 연구
오준,장행진,김상채 木浦大學校 工業技術硏究所 1998 工業技術硏究誌 Vol.8 No.-
Chromatographic experiments in packed bed have been carried out for nitrogen and oxygen adsorption on molecular sieves 13X at room temperature and the pressure range of 1~5 atm. Adsorption equilibrium constant (K_A) and effective diffusivities (D_e) determined by time domain analysis decrease with increasing pressure. and it is shown that the results can be expressed in the following forms: N_2-MS13X adsorption system : K_A = 5.65 P^-0.15 D_e = 8.25×10^-3 P^-0.69 O_2-MS13X adsorption system : K_A = 2.24 P^-0.10 D_e = 7.50×10^-3 P^-0.72
국가 Grid 기본 계획과 국·내외 Grid 프로젝트 추진 동향
장행진(Haeng Jin Jang),박형우(Hyoung Woo Park),이상산(Sangsan Lee) 한국전산유체공학회 2001 한국전산유체공학회 학술대회논문집 Vol.2001 No.-
Advanced countries centered by National Supercomputing Center are inclined to construct Grid Infra and develop key applications in high performance computing field. They are also trying to globalize the Grid project aided by research groups in nations and continents. Computing technology and application development in Grid computing environment become indirect capital of high performance computing and information technology, Therefore, Korean government would like to participate in their Grid construction and application development actively and pursue to Grid project to develop Grid industries such as IT, BT, next five years,
Lee, Seung Jin,Yeo, Jeong Seok,Lee, Haeng Jung,Lee, Eun Jung,Kim, Seog Young,Jang, Se Jin,Lee, Jong Jin,Ryu, Jin-Sook,Moon, Dae Hyuk Springer-Verlag 2014 European Journal of Nuclear Medicine and Molecular Vol.41 No.7
<P>Thymidine phosphorylase (TP), a key enzyme in the pyrimidine nucleoside salvage pathway, catalyses the reversible phosphorylation of thymidine, thereby generating thymine and 2-deoxy-D-ribose-1-phosphate. By regulating the levels of endogenous thymidine, TP may influence [(18)F]fluorothymidine ([(18)F]FLT) uptake. We investigated the effect of TP activity on [(18)F]FLT uptake by tumours.</P>
생약추출물 유도형 Nitric Oxide Synthase 저해활성 검색
류재하,이소영,박재현,이화진,장세란,은진희,김남이,정연수,장미경,최영은,이숙현,손행자,안한나,고혜진 숙명여자대학교 약학연구소 2001 약학논문집-숙명여자대학교 Vol.17 No.-
Nitric Oxide (NO), derived from L-arginine, is produced by two types (constitutive and inducible) of nitric oxide synthase (NOS: cNOS and iNOS). The NO produced in large amounts by the iNOS is known to be responsible for the vasodilation and hypotension observed in septic shock and inflammation. The inhibitors of iNOS, thus, may be useful candidate for the treatment of inflammatory diseases accompanied by the overproduction of NO. We prepared alcoholic extracts of herbal drugs which have been used for the treatment of inflammation in oriental medicine. We have screened the inhibitory activity of NO production in lipopolysaccharide (LPS)-activated macrophages after the treatment of these extracts. Among the 81 kinds of extracts of herbal drugs, 34 extracts showed potent inhibitory activity of NO production above 50% at the concentration of 50 (μg/ml. The inhibitory activities of NO production were also evaluated for several solvent fractions at three different concentrations. Especially, hexane soluble fractions of Agrimonia pilosa, Hydrangea serrata, Machilus thunbergii, Prunella vulgaris, Saussurea lappa, Tussilago farfara, and ethyl acetate soluble fractions of Angelica gigas, Ostericum koreanum, Torilis japonica, Perilla frutescence showed moderate activity at 10 and/ or 25 (μg/ml. These fractions are promising candidates for the study of the activity-guided chromatographic purification of active compounds.
Jang, Jun-Bock,Yoon, Young-Jin,Park, Jung-Hyun,Jeong, Haeng-Gyu,Cho, Jung-Hoon,Ko, Seung-Gyu,Lee, Chang-Hoon,Lee, Jin-Moo,Lee, Kyung-Sub Elsevier 2009 COMPLEMENTARY THERAPIES IN MEDICINE Vol.17 No.3
<P><B>Summary</B></P><P><B>Objective</B></P><P>This clinical study was conducted to investigate the efficacy and safety of an oriental herbal medicine native to Korea, <I>Chiljehyangbuhwan</I>, in treating primary dysmenorrhea.</P><P><B>Design and setting</B></P><P>A total of 100 primary dysmenorrhea patients who visited Kyung Hee University Korean Oriental Medicine Hospital between July 19 2004 and August 27 2004 were recruited. Secondary or drug-related dysmenorrhea was screened out through interviews and examination. The patients were grouped by fixed blocked randomization and administered either <I>Chiljehyangbuhwan</I> or placebo for one menstrual period in a double blind model. Visual Analogue Scale (VAS), Verbal Rating Scale (VRS), and Multidimensional Verbal Rating Scale (MVRS) were used to evaluate dysmenorrhea severity. A total of 71 patients who passed the screening test and remained to the last were divided into either placebo or <I>Chiljehyangbuhwan</I> group, and each were further split into smaller subsets (indication, non-indication, and unspecified group) according to Korean Oriental medical diagnosis.</P><P><B>Results</B></P><P>In the non-indication group, the placebo and <I>Chiljehyangbuhwan</I> group did not show significant difference in VAS, VRS, and MVRS scores before medication (1st VAS, 1st VRS, 1st MVRS), after medication (2nd VAS, 2nd VRS, 2nd MVRS), and in changes in scores before and after (ΔVAS, ΔVRS, ΔMVRS). In the indication group, the placebo and <I>Chiljehyangbuhwan</I> group showed significant difference in change in VAS and MVRS scores (ΔVAS and ΔMVRS). No evidence of toxicity could be found, and no serious adverse reactions to <I>Chiljehyangbuhwan</I> were reported.</P><P><B>Conclusion</B></P><P>The results suggest that <I>Chiljehyangbuhwan</I> is effective and safe in treating primary dysmenorrhea when prescribed appropriately under Korean Oriental medical diagnosis.</P>
Jang, Hye Yeon,Kim, Do Hyung,Lee, Haeng Jung,Kim, Won Dong,Kim, Seog-Young,Hwang, Jung Jin,Lee, Seung Jin,Moon, Dae Hyuk Elsevier 2019 Biochemical pharmacology Vol.160 No.-
<P><B>Abstract</B></P> <P>Combination of MEK inhibitor and 5-FU had showed limited efficacy in clinical trials. We previously reported that acquired resistance to 5-FU was related with continued activation of <I>salvage</I> pathway. Here we investigated whether combination of 5-FU and a MEK inhibitor had treatment sequence-dependent synergistic effects in <I>KRAS</I> or <I>BRAF</I> mutant colon cancer models. Treatment with 5-FU followed by selumetinib (FS) induced highest cell death and synergy compared with reverse (SF) and concomitant (cFS) treatment in six cell lines. SF or cFS combination induced synergy in 1 or 2 cell lines, respectively, in which the synergy was less than that by FS combination. FS enhanced apoptosis and decreased anchorage-independent growth. Induction of thymidine kinase 1, a rate-limiting enzyme in <I>salvage</I> pathway, by 5-FU was abrogated by subsequent treatment with selumetinib, and ERK reactivation after selumetinib was prohibited by pretreatment with 5-FU. FS altered mRNA expression in groups of genes distinct from SF. Administration of 5-FU (10 or 30 mg/kg/day) for 7 days, followed by selumetinib (10 or 25 mg/kg/day) for another 7 days, in colo205 and HCT8 xenograft models significantly decreased tumor growth compared with a single agent. However, co-administration in the reverse sequence did not show the difference in tumor size compared with the treatment of single agent. Decreased expression of Ki67 was observed in tumors from mice treated with FS. Our results suggest that sequential administration of 5-FU plus selumetinib would be a promising strategy for patients having <I>KRAS</I> or <I>BRAF</I> mutant colon cancers.</P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>